LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Flow Cytometry-Based Method Analyzes Heinz Bodies

By LabMedica International staff writers
Posted on 26 Jan 2017
Image: Heinz bodies in red blood cells from a patient with Glucose-6-phosphate dehydrogenase deficiency (Photo courtesy of the School of Medicine UC Davis).
Image: Heinz bodies in red blood cells from a patient with Glucose-6-phosphate dehydrogenase deficiency (Photo courtesy of the School of Medicine UC Davis).
Heinz bodies are inclusions within red blood cells (RBCs) that are composed of denatured hemoglobin molecules and are a highly sensitive indicator of in vivo oxidative stress. Heinz body formation has also been reported in chronic liver disease and α-thalassemia patient.

Historically, light microscopes have been used to visualize specially stained Heinz bodies, which can be seen as spherical inclusions at the peripheries of RBCs. However, microscopic examination of Heinz bodies is time-consuming, labor intensive, and of low sensitivity.

Scientists at the Chulalongkorn University and their associates collected whole-blood samples from patients deficient in Glucose-6-phosphate dehydrogenase (G6PD) and healthy volunteers. The study's G6PD-deficient group included patients who had previously been diagnosed. These subjects were apparently healthy and ranged in age from 25 to 45 and none had ever experienced an acute hemolytic crisis or had experienced fever, inflammation, or infection.

Washed RBCs were incubated in the acetylphenylhydrazine solution at 37 °C. After incubating for one hour, the Heinz bodies were counted under a light microscope at ×100. G6PD enzyme activity was determined using the G6PD assay kit. Enzyme activity was determined using a temperature-regulated spectrophotometer by measuring the change in rate in absorbance at 340 nm. RBCs positive for Heinz bodies were examined using a FACSCanto II cytometer.

The investigators found that RBCs treated with acetylphenylhydrazine formed Heinz bodies and emitted a broad spectrum of fluorescence that could be detected by flow cytometry. The maximum emission of fluorescence was observed at 45 minutes after the incubation with acetylphenylhydrazine. In addition, the fluorescence emitted was stable for at least 72 hours. The flow cytometer could detect the RBCs positive for Heinz bodies even if they made up as little as 0.1% of the total RBC population. Furthermore, the percentage and number, respectively, of RBCs positive for Heinz bodies in G6PD-deficient patients and normal donors exhibited a mean ± standard deviation (SD) of 68.9 ± 27.5 versus 50.9 ± 28.6 and 96,014 ± 35,732 cells/μL versus 74,688 ± 36,514 cells/μL.

The author concluded that Heinz bodies induced by acetylphenylhydrazine emit fluorescence, and this fluorescence could be examined using flow cytometry. Their study suggests the potential use of the developed method to investigate the formation of Heinz bodies in clinical samples. The study was published on January 16, 2017, in the International Journal of Laboratory Hematology.

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more